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Abstract 
The transcription factor E2F is an important modulator of the cell cycle, and the unrestricted 
activation of E2F-dependent transcription is considered to be an important driver of tumor 
formation and progression. E2F8 is known to play an important role in embryonic development and 
cell cycle control by inhibiting E2F1. However, it is not yet known whether E2F8 is involved in the 
progression of cervical cancer. In this study, the functional consequences of E2F8 knockdown in vitro 
and in vivo were explored. To demonstrate the function of E2F8 in cell proliferation, migration and 
invasion, we knocked down E2F8 in cervical cancer cell lines; in vitro and in vivo experiments using 
this knockdown showed that E2F8 potently induced the expression of epithelial-mesenchymal 
transition (EMT) markers. Finally, clinical data confirmed that E2F8 was a significant predictive factor 
for progression-free survival, and that patients with cervical cancer who exhibited high expression 
of E2F8 showed high FIGO stages and frequent recurrence rates compared to patients with low 
E2F8 expression. In conclusion, our study suggests that E2F8 is highly correlated with the 
progression-free survival of cervical cancer patients. 
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Introduction 
As one of the most common malignant 
gynecological tumors, cervical cancer is responsible 
for 10 to 15% of all female cancer related deaths 
worldwide and is the second leading cause of death 
from female cancers, exceeded only by breast cancer 
[1, 2]. Moreover, cervical cancer is associated with a 
high risk of morbidity and mortality due to metastasis 
and recurrence [3, 4]. Therefore, biomarkers of early 
prognosis, metastasis and novel treatment targets are 
urgently needed to improve the survival of cervical 
cancer patients. 
Recent studies have shown that the E2F family of 
transcription factors has many regulatory functions 
involved in cell proliferation, differentiation, DNA 
repair, cell cycle and apoptosis [5, 6]. So far, the E2F 
family has eight members, named E2F1 to E2F8. 
Depending on structure and function, the E2F family 
can be divided into two groups (standard E2F1-6 and 
unstructured E2F7-8) and four subgroups (E2F1-3a, 
E2F3b-5, E2F6 and E2F7-8). There is also evidence that 
E2F7/8 is involved in the transcriptional suppression 
of the cell cycle gene for seven or eight years of DNA 
damage [7, 8]. Although the exact role of E2F7 / 8 in 
DNA damage is not clear, transcription in cell cycle 
processes that enable optimal DNA recovery is one 
possibility because high levels of E2F7 / 8 were 
shown to inhibit proliferation within the laboratory 
[9]. Particularly, recent literature reported that 
expression of E2F8 was markedly enhanced in 









in oncogenesis and cancer progression [10]. However, 
the biological role and clinical significance of E2F8 in 
the progression of cervical cancer has not yet been 
identified in relation to the epithelial-mesenchymal 
transition (EMT).  
In this study, we investigated the functional role 
of E2F8 in the progression of cervical cancer. Our 
results show that E2F8 strengthened the growth, 
migration, and invasion of cervical cancer cells 
through an EMT signaling pathway. Our study 
suggests that E2F8 is a promising prognostic factor 
and target for cervical cancer treatments. 
Materials and Methods 
Patients and tissue samples 
In total, 80 women who underwent surgery 
between 2012 and 2018 at Yonsei Severance Hospital, 
Yonsei University, seoul, korea, were included in this 
study. This study was conducted according to the 
principles of the Helsinki Declaration and ethical 
guidelines of the Yonsei Severance Hospital Ethics 
Committee. A sample of newly diagnosed stage IA to 
IVB cervical cancer (international gynecology and 
gynecology) was evaluated without prior diagnosis. 
Additionally, normal cervical tissues from 20 patients 
undergoing simple hysterectomies because of uterine 
leiomyomata were obtained as controls. The study 
was approved by the Yonsei Severance Hospital 
Ethics Committee and approved by all patients. All 
samples were immediately frozen in liquid nitrogen 
until RNA extraction and stored at -80°C. 
Cell lines 
Human epithelioid cervical adenocarcinoma 
(HeLa) cells were obtained from the Korean Cell Line 
Bank (Seoul, Korea). The epidermoid cervical cancer 
carcinoma line, established from transfer in small 
intestine (Caski cells) and ME180 cells, was obtained 
from the American Type Culture Collection (ATCC, 
Rockville, MD, USA). Human keratinocyte HaCaT 
cells were obtained from the Creative Bioarray 
(Shirley, NY, USA).  
HeLa cells were cultivated in Dulbecco's 
modified Eagle's medium (WelGENE Inc, Korea) and 
Caski, ME180 and HaCaT cells were cultivated in the 
RPMI-1640 media (WelGENE Inc., Korea). The culture 
medium contained 10% (vol/vol) fetal bovine serum 
and penicillin/streptomycin. The cell lines were 
maintained at 37°C in humidified air with 5% CO2 
and 95% air. The passage number of cells was <20 in 
all experiments. 
Quantitative real-time PCR (qRT-PCR) 
RNA was extracted from cancer tissues or 
cultured cells using TRIzol reagent (Bioline, London, 
UK). In accordance with the manufacturer's 
instructions, the total RNA was reversed to cDNA 
using the reverser reagent kit (Bioline). Real-time PCR 
analyses were conducted employing a SYBR Green 
Real-Time PCR Kit (Bioline). Settings for the 
amplification of E2F8 were as follows: initial 
denaturation at 95℃ for 3 minutes, 40 cycles with 
denaturation at 95℃ for 15 seconds, annealing at 60℃ 
for 60 seconds, and elongation at 72℃ for 60 seconds, 
then final elongation at 72℃ for 5 minutes. qRT-PCR 
was accomplished using an ABI StepOnePlus 
Real-Time PCR System (Applied Biosystems, Foster 
City, CA, USA). The results were normalized with the 
expression of U6. The relative change in the 
expression of mRNA was calculated by the 2-ΔΔCT 
method. All qRT-PCR experiments were replicated at 
least three times. 
Small interfering RNA (siRNA) transfection 
E2F8 siRNA (siE2F8) and negative control 
siRNA (siNC) were obtained from Genolution 
(Genolution Pharmaceuticals Inc., Seoul, Korea). 
Seeded cells (5 x 104 cells/well) into 6-well plates, 
using the G-fectin Kit (Genolution Pharmaceuticals) 
in accordance with the manufacturer's instruction for 
transfection with 30 nM siRNA in phosphatebuffer 
saline (PBS). The siRNA−transfected cells were used 
in in vitro assays 48 hours after transfection. The 
experiments were repeated at least three times. 
E2F8 gene silencing by shRNA 
Target shRNA sequences against human E2F8 
were designed based on the sequence available from 
the Gene Bank. The sequence of the E2F8 shRNA was 
TRCN0000017428: 5’-GCCGCAAAGACAAGTCTTT 
AA-3’. Oligonucleotides were formed by annealing, 
then the constructs were cloned into the pLKO.1 
vector. HEK293T cells were transfected with 
shRNA-coded lentiviral vector DNA and packaging 
vectors (pCMV-VSVG, psPAX2, and pMC2.G) using 
Lipofectamine 2000 (Life Technologies, Carlsbad, CA, 
USA). The viral medium was collected at both 48 and 
72 hours post-transfection. Cells were infected in the 
viral medium along with 8 ㎍/ml polybrene, followed 
by selection with puromycin.  
Cell proliferation assay 
The Cell Counting Kit-8 (CCK-8, Dojindo, Japan) 
assay was used to assess cell proliferation. Cells (5 x 
104 cells/well) were seeded into 6-well flat-bottomed 
plates in 2 mL of complete medium. After incubation 
of cells overnight to allow for cell attachment and 
recovery, the cells were transfected with siNC or 
siE2F8 for 24, 48, 72 or 96 hours. An aliquot of 200 μL 
of the CCK-8 solution was added to each well and 





incubated for 1 hour at 37°C. The optical density (OD) 
was measured at 450 nm using an auto-microplate 
reader to calculate the number of viable cells in each 
well. The assay was performed in triplicate. 
Colony formation assay 
ME180 cells were transfected with shE2F8 or 
scrambled (5 x 104) suspensions and then incubated in 
an upper layer of 1% agar noble (A5431 
Sigma-Aldrich, St. Louis, MO, USA) in 2x RPMI with 
10% fetal bovine serum. The suspension was overlaid 
on 0.6% basal agar with 10% fetal bovine serum in a 
6-well plate and placed at room temperature until the 
agarose solidified. The plate was transferred to a 5% 
CO2 incubator, incubated at 37°C for 3 weeks, and 
stained with crystal violet. Colonies with a diameter 
greater than 0.5 mm were counted using the ImageJ 
software (NIH Bethesda, MD, USA). 
Wound healing migration assay 
Cell migration was evaluated with a wound 
healing assay. About 5 x 105 cells were seeded into 
6-well plates with serum-containing medium and 
allowed to grow to 90% confluency in complete 
medium. The serum-containing medium was 
eliminated and the cells were serum starved for 24 h. 
When the cell density reached 100%, artificial 
homogenous wounds were created by scratching a 
single layer using a sterile 200 μL pipette tip. After 
scratching, the cells were washed with phosphate 
buffer saline (PBS). Using the microscope, cell 
migration into the wound were captured for 0, 24, and 
48 h. The width of the scratch was measured using the 
NIH ImageJ software and calculated as the percentage 
of the closed scratch area (width at 0 h / width 48 h). 
The results were standardized to control cells. The 
migrated cells were counted in 10 fields under an 20x 
objective lens. Original magnification as 200x. The 
experiments were performed in triplicate. 
Transwell migration assay 
The migration assay was designed using 6.5 mm 
diameter Transwell plates (Corning Costar, 
Cambridge, MA, USA) with 8 μm pore filters. Cells (5 
x 105) were seeded in the upper chamber in 
serum-free medium and complete medium was 
added to the lower chamber. Cells were incubated for 
48 hours in the migration chamber set to 37°C and 5% 
CO2. Non-invasive cells were removed from the 
upper chamber with a cotton swab. The cells that 
intruded into the lower surface of the filter were dyed 
(Diff Quik, Sysmes, Kobe, Japan) and counted with a 
hemocytometer. This assay was repeated at least three 
times. 
Matrigel invasion assay  
The Matrigel invasion assay was performed 
using BD Biocoat Matrigel Invasion Chambers (pore 
size: 8 mm, 24-well; BD Biosciences, Bedford, MA, 
USA) according to the manufacturer's protocol. Cells 
(5 x 105) were seeded in the upper chamber in 
serum-free medium and complete medium was 
added to the lower chamber. Cells were incubated for 
48 h in the Matrigel invasion chamber set to 37°C and 
5% CO2. Non-invasive cells were removed from the 
upper chamber with a cotton swab. The cells that 
entered the lower surface of the filter were stained 
(Diff Quik, Sysmes, Kobe, Japan) and counted with a 
hemocytometer. This assay was repeated at least three 
times. 
Western blot analysis 
RIPA buffer (Thermo Fisher Scientific Inc. 
Waltham, MA, USA) was used to extract proteins. We 
measured the protein concentrations using a Pierce 
BCA Protein assay kit (Thermo Fisher Scientific). The 
protein was boiled with a 5x sample buffer to dissolve 
it further in a 10% SDS-polyacrylamide gel, followed 
by electrophoretic transfer to a polyvinylidene 
difluoride membrane (Milipore, Billica, MA, USA). 
After blocking with 5% fat-free dried milk in 1x 
Tris-buffered saline containing 0.1% tween 20 (pH 7.6) 
at room temperature for 1 hour, the membrane was 
continuously stirred and incubated with primary 
antibody at 4℃ overnight.  
Xenografts in mice  
BALB/c mice (n = 30, 5–6 weeks of age, Orient 
Bio, Seongnam, Korea) were kept in aseptic conditions 
under constant temperature and humidity (Yonsei 
Medical University protocol). Each mouse received a 
subcutaneous dorsal scapula injection of a 200 μL 
suspension of HeLa cells pretreated with siE2F8 and 
siNC for 48 h (1.0 x 106 cells/flank, xenograft n=18). 
ME180 cells pretreated with shE2F8 or shscrambled 
control were transplanted (2.0 x 106 cells/flank, 
xenograft n=12) into the subcutaneous dorsal scapula 
injection. 
Calipers were used to measure the tumor sizes 
twice a week. The tumor volume was calculated using 
a simplified equation to estimate a rotational ellipsoid 
(length x width2 x 0.5). Each tumor was harvested 40 
days post-treatment.  
Magnetic resonance (MR) imaging in mice  
MR images were obtained using Brucker Biospec 
94/24 USR (9.4T) small animal scanner (35 mm 
diameter cage coil, Brut BioSpin MRI, Ettlingen, 
Germany). A custom-built cradle was used to 
immobilize each mouse during the MR imaging 





process. At the beginning of each imaging session, the 
T2-weighted image was obtained using the quick 
acquisition setting. These images were used to 
confirm that the animal was in the correct position 
inside the magnetic bore. A 1.5% isoflurane and 
O2/N2O (1:1) mixture at a 0.7 L/min flow rate was 
used as anesthesia during the MR imaging. Breathing 
was monitored using an air pillow. The body 
temperature of the mice was maintained within 
acceptable limits using circulating warm water. 
Hematoxylin and eosin (H&E) staining 
Mice were euthanized after the MRI. Tumor 
tissue was collected, fixed with 4% paraformaldehyde 
for 24 h, washed in PBS, and then embedded in 
paraffin. Two-micrometer sections were stained with 
hematoxylin and eosin following standard 
procedures. 
Statistical analyses 
IBM SPSS version 24 for Windows (SPSS Inc., 
Chicago, IL, USA) was used for statistical analyses. 
We used Pearson's χ2 tests, Student's t-tests, and 
Fisher's exact tests to evaluate the associations 
between E2F8 expression and clinicopathological 
characteristics. In order to evaluate the performance 
of the model with respect to their discriminating 
capability, the chi-square value of the log rank test 
was used in the receiver operating characteristic 
(ROC) analysis. The median value (1.2962) was set to 
the cutoff value. These groups were classified as high 
and low E2F8 expression groups, respectively, at the 
above and below values of the cut-off value of 1.2962. 
The entire survival time was analyzed using the 
Kaplan-Meier method. The log rank test was used to 
estimate the differences between groups. The 
stepwise Cox proportional hazards model was used 
for multivariate survival analysis of the parameters 
which were significant in the univariate analysis. The 
statistical tests were two-sided and p-values of less 
than 0.05 were considered significant. 
Results 
E2F8 expression was elevated in cervical 
cancer and correlated with poor prognosis 
To determine whether E2F8 expression in tissues 
was associated with the clinicopathologic 
characteristics of cervical cancer, we evaluated the 
expression of E2F8 in cervical cancer tissue (n =80) 
and corresponding normal tissue (n =20). The E2F8 
expression in cervical cancer tissues was more than 
11.07 times that of non-cancerous tissues (p= 0.001; 
Figure 1A). 
 The risk model for E2F8 data showed a 
predicted AUC of 0.892 (p= 0.00000007; Figure 1B.). 
We compared the characteristics of patients with high 
E2F8 expression (n=62) to those with low E2F8 
expression (n=18; Table S1). Kaplan-Meier survival 
analysis demonstrated that cervical cancer patients 
with low E2F8 levels exhibited 
longer overall survival and 
disease-free survival than cervical 
cancer patients with high E2F8 
levels (p=0.035 and 0.028, 
respectively Figure 1C and D).  
Moreover, according to uni-
variate and multivariate analyses 
using the Cox proportional 
hazards model, E2F8 expression 
was a significant predictive factor 
for stage and recurrence (stage, 
univariate hazard ratio (HR)= 
1.844 (1.276-2.663), p=0.001, 
multivariate HR=1.816 (1.258- 
2.622), p=0.001; recurrence, uni-
variate HR=7.545 (3.535-16.103), 
p=0.000000017, multivariate HR= 
7.823 (3.605-16.973), p=0.0000001; 
Table 1). Both univariate and 
multivariate proportional hazard 
analyzes showed that stage and 
recurrence were independent 





Figure 1. The clinical significance of E2F8 expression in cervical cancer tissue. (A) The E2F8 
expression was significantly higher in cervical cancer tissues (n=80) than in non-cancerous tissues (n=20). E2F8 
expression was determined using qRT-PCR and is expressed relative to the control value. Data are expressed 
as mean ± SD. * * p<0.01 vs. non-tumor control. (B) ROC curve for prognostic predictions for patients by E2F8 
levels. The AUC is shown in the plots. ROC, receiver operating characteristic; AUC, area under the curve. (C) 
Kaplan-Meier curves for the overall survival and (D) disease-free survival of cervical cancer patients with 
different expression levels of E2F8. 





Table 1. Univariate and multivariate analysis of various factors for overall survival 
 OS 
 Univariate analysis  Multivariate analysis 
 HR (95% CI) P  HR (95% CI) P 
E2F8 expression 1.108 (0.481-2.556) 0.809    
Age, years (continuous) 1.003 (0.974-1.033)  0.837    
FIGO stage 1.844 (1.276-2.663) 0.001  1.816 (1.258-2.622) 0.001 
cell type 1.026 (0.720-1.461) 0.889    
Lymph node metastasis 1.939 (0.977-3.847) 0.054    
Lymphovascular invasion 1.385 (0.658-2.915) 0.39    
Recurrence 7.545 (3.535-16.103) 0.000000017   7.823 (3.605-16.973) 0.000000195  
tumor size 1.365 (0.849-2.195) 0.199    
OS, overall survival; HR, hazard ratio; FIGO, The International Federation of Gynecology and Obstetrics 
 
E2F8 expression was elevated in cervical 
cancer cell lines and correlated with cell 
proliferation 
To investigate the E2F8 expression in cervical 
cancer cells, several cell lines were examined for 
mRNA and protein levels of E2F8 (Figure 2A and B). 
As shown in Figure 2, CaSki, HeLa, and ME180 cells 
expressed higher levels of E2F8 than the control 
(HaCaT) cells. Next, we examined the effects of E2F8 
in cervical cancer cells. By transfecting siE2F8 and 
shE2F8, E2F8 was knocked down in HeLa and ME180 
cells. The siE2F8 and shE2F8-transfected HeLa and 
ME180 cells also showed significant 
inhibition of cell proliferation (Figure 2C 
and E). E2F8 inhibited cell proliferation by 
50% and 60% at 72 h post-transfection in 
HeLa and ME180 cell lines, respectively, 
relative to control cells (Figure 2D and F). 
Thereafter, colony formation assays 
confirmed that E2F8 inhibited cell colony 
formation and by 90% in ME180 cell lines 
relative to control cells (Figure 2G and F). 
 
E2F8 knockdown inhibited the 
migration and invasion of cervical 
cancer cells 
We investigated whether E2F8 affects 
the invasion and migration of cervical 
cancer cells. A Matrigel invasion assay 
was used to assess invasion after 48 h. 
E2F8 knockdown in cervical cancer cell 
lines (HeLa and ME180) showed 
significant decrease in wound-healing. 
Therefore, the same cell lines were used to 
assess migration in si- and sh-E2F8 
transfected cervical cancer cells (Figure 3A 
and C). In addition, the invasiveness of 
these cells was compared to that of control 
cells. The E2F8 knockdown cells exhibited 
reduced invasiveness (Figure 3B and D). 
While uncontrolled cell proliferation is a 
common biological feature of all tumors, 
the key pathophysiological feature of 
malignant tumors in pathological 
conditions is the ability to penetrate the 
natural tissue barrier. Our findings 
suggest that E2F8 expression correlated 
with cancer invasion and metastasis. 
 
 
Figure 2. E2F8 expression in cervical cancer cell lines and correlation with 
suppressed cell proliferation. (A, B) The expression levels of E2F8 RNA and protein were 
significantly higher in some cervical cancer cell lines (CaSki, HeLa, and ME180) compared to that in 
normal control cells. (C) Using siE2F8, E2F8 knockdown was performed in E2F8-elevated HeLa 
cell lines. (D) The proliferation of HeLa cells transfected with siE2F8 and negative control siNC 
was determined using the CCK-8 assay. (E) Using shE2F8, E2F8 knockdown was performed in 
E2F8-elevated ME180 cell lines. (F) The proliferation of ME180 cells transfected with shE2F8 and 
negative scrambled control was determined using the CCK-8 assay. Each assay was performed in 
triplicate. Data are means ± standard deviation. **P<0.01, ***P<0.001 vs siNC and scrambled 
control. 






Figure 3. E2F8 promotes cell migration and invasion. (A, C) Wound healing assay observed under the optical microscope was used to determine cell 
migration using si and shE2F8. E2F8 knockdown was performed in E2F8-high HeLa and ME180 cell lines. (B, D) Cell invasion was observed under the optical 
microscope. Matrigel invasion assays were used to determine invasion after 48 h in HeLa and ME180 cells. Each assay was performed in triplicate. Data represent 
means ± standard deviation. **P<0.01, ***P<0.001 vs. siNC and scrambled control. 
 
E2F8 knockdown reversed EMT signaling 
pathway-related genes in cervical cancer cells 
Because EMT is crucial in cell migration and 
invasion, the identification of factors associated with 
EMT can have a clinical impact [11, 12]. Thus, we 
examined whether E2F8 was associated with EMT. 
Towards this, EMT-related markers were evaluated 
using real-time RT-PCR (Figure S1A and 4A) and 
Western blotting (Figure S1B and 4B) after the si- and 
sh-RNA-mediated knockdown of E2F8 in HeLa and 
ME180 cells. Knockdown of E2F8 increased 
E-cadherin expression and decreased the expression 
of N-cadherin, b-catenin, vimentin, Wnt5, and Twist. 
These results indicate that the dysregulation of 
EMT-related genes may explain the involvement of 
E2F8 in cervical cancer cell migration and invasion. 





E2F8 knockdown blocked tumor growth in a 
xenograft nude mouse model 
To explore whether E2F8 affected tumor growth 
in vivo, we implanted HeLa and ME180 cells, in which 
E2F8 was knocked down, as xenografts into nude 
mice (Figure S2A and Figure 5A). Tumor volume 
(Figure S2B and Figure 5B) and weights (Figure S2C 
and Figure 5C) were measured. The mean tumor 
volumes and weights of mice, which were implanted 
with siE2F8 transfected HeLa cells and shE2F8 
transfected ME180 cells were significantly smaller 
than those of mice that had been impalnted with si- 
and sh-scrambled control cells (p < 0.05. Histological 
examination revealed that more cells with small 
nucleoli and irregular nuclear membranes were 
present in the E2F8 knockdown xenografts than that 
in the control xenografts (Figure S2D 
and Figure 5D). We further evaluated 
tumor size and activity using magnetic 
resonance imaging (MRI) (Figure S2E 
and Figure 5E). These findings 
suggested that E2F8 promoted tumor 
growth in vivo, and further supported 
our hypothesis that E2F8 is involved in 
the malignant transformation of 
cervical cancer cells. 
Discussion 
The deregulation of E2F- 
dependent transcription occurs 
frequently in many cancers and is 
considered an important factor in the 
uncontrolled proliferation of cancer 
cells. However, the function and 
contribution of E2F family members in 
various types of cancers is complex and 
poorly understood [13]. Most studies 
have indicated that E2F deregulation in 
tumors is a result of overexpression of 
proliferation‐promoting transcription 
factors, rather than deregulation of the 
mainly inhibitory transcription factors. 
In non–small cell lung cancer and 
esophageal squamous cell carcinoma, 
tumor progression and poor outcomes 
correlate with overexpression of the 
proliferation‐promoting transcription 
factor E2F1 [14, 15]. In contrast, tumor 
growth is enhanced by the 
downregulation of inhibitory E2F 
transcription factors such as E2F4 and 
E2F7, and such an imbalance may 
cause a switch from cell quiescence to 
growth promotion [16]. E2F protein is a 
proven modulatory factor in malignant 
progression in various cancers. The 
newly identified E2F8 has been 
reported to be an important prolifera-
tion factor in some human cancers [17]. 
A deeper understanding of the 
molecular mechanisms that determine 
the progression and metastasis of 
cervical cancer is essential for the 
 
 
Figure 4. Effect of E2F8 Knockdown on EMT progression. (A) ME180 cells were transfected 
with shE2F8 or scrambled control. Real-time RT-PCR of EMT-related transcription factors after E2F8 
knockdown in ME180 cells. Data represent means ± SD. **P<0.01, ***P<0.001 vs. scrambled control. 
(B) Protein lysates were prepared using shE2F8- and scrambled control-transfected ME180 cells. 





development of more effective therapies and for the 
identification of new diagnostic indicators of cervical 
cancer.  
Recent studies have shown that some abnormal 
molecular changes can play a central role in the 
development of cervical cancer [18]. However, the 
clinical significance and biological function of E2F8 in 
gynecological cancer, especially cervical cancer, 
remains unknown. Accordingly, in this study, the 
molecular function and clinical significance of E2F8 
expression was investigated in cervical cancer cell 
lines. We found that E2F8 expression was higher in 
cervical cancer tissues than that in non-cancerous 
tissues. Moreover, E2F8 knockdown altered the cell 
growth, migration, and invasion of cervical cancer 
cells. The metastatic effects of E2F8 appeared to be 
mediated, at least in part, by regulation of the genes 
involved in cell migration, invasion, and EMT. 
 
 
Figure 5. E2F8 knockdown decreases tumor size in a xenograft nude mouse model. (A) ME180 cells transfected with shE2F8 or scrambled control were 
injected subcutaneously into the right dorsal scapula area of nude mice. Gross images of tumor masses from representative mice from each group. (B) Tumor sizes 
in the experimental groups. (C) Tumor weights were compared after tumor harvest. (D) Hematoxylin and eosin (H&E) staining of shE2F8-transfected ME180 cells 
(x200). (E) MRI image. *p<0.05 vs. scrambled control. 





There is some evidence that E2F8 might also be 
associated with human cancers. An increase in the 
E2F8 gene copy number was detected in melanoma 
[19] and increased expression was reported in ovarian 
cancer and hepatocellular carcinoma [20]. E2F8 
knockdown caused an almost complete block of cell 
proliferation and a substantial induction of apoptosis, 
but did not inhibit normal bronchial epithelial cell 
growth. These results indicate that while E2F8 does 
not serve a role in normal cells, it plays an integral 
role as a tumor promoter in cancer cells.  
To better understand the direct role of E2F8 in 
carcinogenesis, we targeted EMT signaling by 
knockdown of E2F8. The EMT involves alterations in 
cell phenotypes and several transcription factors have 
been implicated in the regulation of EMT-related gene 
expression. Although several studies have focused on 
transcriptional regulators in pathological EMT, few 
studies have evaluated the roles of transcription 
factors in cervical cancer [21]. The present study 
explored the molecular function of E2F8 expression in 
cervical cancer cell lines. Our findings showed that 
downregulated E2F8 expression was correlated with 
decreased cell growth, migration, and invasion of 
cervical cancer cells. This effect of E2F8 on tumor 
progression may be mediated by genes involved in 
cell migration, invasion, and the EMT signaling 
pathway, as well as genes that encode E-cadherin, 
N-cadherin, β-catenin, vimentin, and Snail. Our 
findings suggested that E2F8 could potentially 
represent a novel biomarker and therapeutic target for 
cervical cancer. The loss of E-cadherin is thought to be 
an important event in the EMT, but N-cadherin 
reduces the intercellular connection between two 
adjacent endothelial cells, causing the cancer cells to 
slip [22]. In addition, β-catenin is more slowly mobile 
and weakens the related mesenchymal phenotype. 
The improvement in the expression of transcription 
factors, such as in snail and twist, is related to the loss 
of adhesion between cells [23]. Vimentin is the main 
component of the cytoskeleton of mesenchymal cells 
and its upregulation is induced by the EMT [24, 25].  
We hypothesized that E2F8 may act as an 
important regulator for several signaling mechanisms 
related to the EMT. Our results suggest that E2F8 can 
contribute to the growth, invasion, and recurrence of 
cervical cancer through induction of the EMT. The 
recurrence rate of advanced cervical cancer after 
radical surgery is 15 to 30% and the prognosis of 
patients with recurrence is poor [26]. In order to 
improve the prognosis of cervical cancer patients, a 
firm prediction of relapse and progression is needed. 
The EMT signaling pathway contributes to tumor 
progression characteristics, including invasion, 
metastasis, and angiogenesis [27]. Furthermore, 
clinical outcome data from 80 patients with epithelial 
cervix cancer support the findings of our in vitro 
experiments.  
In summary, our research suggests that E2F8 is 
correlated with the progression of cervical cancer via 
EMT signaling pathways. These results support E2F8 
as a promising prognostic marker and therapeutic 
target for cervical cancer. 
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